Mogamulizumab is under clinical development by Kyowa Kirin and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL). According to GlobalData, Phase I drugs for Peripheral T-Cell Lymphomas (PTCL) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Mogamulizumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mogamulizumab overview
Mogamulizumab (Poteligeo) is a glyco-engineered humanized monoclonal antibody targeting C-C chemokine receptor 4 (CCR4). It is designed by utilizing the company's Potelligent technology platform. It is formulated as solution and concentrate solution for intravenous route of administration. Poteligeo is indicated for the treatment of CCR4 positive adult T cell leukemia, lymphoma. It is also indicated for recurrent or refractory CCR4 positive peripheral T cell lymphoma and skin T-cell lymphoma. It is also indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sezary syndrome (SS) after at least one prior systemic therapy.
Poteligeo is under development for treatment of oral squamous cell carcinoma, including mycosis fungoides and sezary syndrome, angioimmunoblastic T-cell lymphoma, anaplastic large-cell lymphoma and peripheral T/NK-cell lymphoma. It was also under development for asthma, HTLV-1 associated myelopathy (HAM) (Spinal cord disorder), peripheral T-cell lymphoma, allergic rhinitis, non-small cell lung cancer, relapsed/ refractory adult T-cell leukemia, and cutaneous T-cell lymphoma, metastatic triple negative breast cancer, metastatic hepatocellular carcinoma, gastric cancer, gastric adenocarcinoma, esophageal squamous cell carcinoma, non-small-cell lung carcinoma and solid tumor. It was also under development for renal cell carcinoma, adenocarcinoma of the gastroesophageal junction, oral cancer..
Kyowa Kirin overview
Kyowa Kirin, a subsidiary of Kirin Holdings Co Ltd, is a biotechnology company focused on research and development. It is involved in the discovery, development, production and commercialization of pharmaceuticals and biotechnology products. The company offers drugs in the areas of nephrology, immunology and allergy, oncology, central nervous system among others. Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, angina pectoris, hypertension, allergic rhinitis, epilepsy, behavioral or personality disorders and others. The company operates through a network of subsidiaries in the US, Europe and Asia. Kyowa Kirin is headquartered in Tokyo, Japan.
For a complete picture of Mogamulizumab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
